This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Rheumatology  • Rheumatology, Other  • Immunologic Disorders  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Lupus erythematosus profundus (LEP) is a clinical subtype of cutaneous lupus erythematosus that has a chronic and recurrent clinical course. Systemic corticosteroids, which are often administered in cases of LEP complicated with systemic lupus erythematosus, are generally effective but cause side effects. Thus, other therapeutic options are needed. Hydroxychloroquine and thalidomide have occasionally been used as first-line therapies for LEP^1-2; however, the sale of them is prohibited in Japan because of their severe side effects. Alternatively, dapsone has been used in Japan. Indeed, there were several case reports written in the Japanese literature describing patients with LEP successfully treated with dapsone; however, few cases have been reported in the English literature.^3-4 Herein we report a case of LEP successfully treated with dapsone, and we review the previous Japanese cases.

Report of a Case

A 56-year-old Japanese woman presented with a 3-year history of erythema on her upper right arm. Over a 2-month period, . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION
Hideyuki Ujiie, MD; Tadamichi Shimizu, MD, PhD; Miki Ito, MD; Ken Arita, MD; Hiroshi Shimizu, MD, PhD

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Women's Dermatologic Diseases, Health Care Delivery, and Socioeconomic Barriers.
Robinson and Ramos-e-Siliva
Arch Dermatol 2006;142:362-364.
FULL TEXT